What are the indications for using extended thrombolytic therapy (extended lysis time) in acute ischemic stroke and in STEMI when primary PCI is unavailable?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Extended Thrombolytic Therapy: Indications and Time Windows

For STEMI when primary PCI is unavailable, fibrinolytic therapy should be administered within 12 hours of symptom onset when anticipated first medical contact-to-device time exceeds 120 minutes, with immediate transfer for angiography within 3-24 hours afterward. For acute ischemic stroke, intravenous thrombolysis can be administered in the extended 4.5-24 hour window when advanced imaging demonstrates salvageable brain tissue (perfusion mismatch or DWI-FLAIR mismatch).

STEMI: Extended Lysis Indications

Standard Time Window (0-12 Hours)

Primary indication: Fibrinolytic therapy is Class I recommended when:

  • Symptom onset within 12 hours 1
  • Anticipated FMC-to-device time >120 minutes at PCI-capable hospital 1
  • No contraindications present 1

Critical timing thresholds:

  • If presenting <2 hours from symptom onset AND PCI delay 60-120 minutes: Either fibrinolysis or PCI acceptable 2
  • If presenting 2-3 hours from symptom onset AND PCI delay 60-120 minutes: Either strategy reasonable (weak recommendation) 2
  • If presenting 3-12 hours from symptom onset AND PCI delay up to 120 minutes: PCI preferred over fibrinolysis 2

Extended Window Considerations (>12 Hours)

Fibrinolysis becomes significantly less effective after 6 hours 2, making PCI the preferred option even with delays >120 minutes in late presenters. However, the 2025 ACC/AHA/SCAI guidelines 3 acknowledge that late presenters with hemodynamic instability or large infarct size may warrant fibrinolysis when timely PCI is impossible, despite lack of established benefit beyond 12 hours.

Absolute indications for PCI regardless of time delay:

  • Cardiogenic shock or acute severe heart failure 1, 4, 1, 5
  • Contraindications to fibrinolytic therapy 1, 5
  • Clinical/ECG evidence of ongoing ischemia 12-24 hours after symptom onset (Class IIa) 4, 5, 4

Post-Fibrinolysis Strategy

Pharmacoinvasive approach: After fibrinolysis administration, immediate transfer to PCI-capable center for routine early angiography within 3-24 hours is Class IIa recommended 4, regardless of apparent fibrinolysis success. This strategy is reasonable when long delays to primary PCI (>120 minutes) are anticipated 2.

Rescue PCI: Immediate angiography with intent to perform PCI is Class IIa reasonable for moderate-to-large area of myocardium at risk with evidence of failed fibrinolysis 4.

Acute Ischemic Stroke: Extended Window Thrombolysis

Standard Window (0-4.5 Hours)

Intravenous alteplase (0.9 mg/kg, maximum 90 mg) remains Class I recommended within 4.5 hours of symptom onset 6, 7.

Extended Window (4.5-24 Hours)

Imaging-based selection is mandatory for extended window treatment. Two validated approaches exist:

MRI-based selection (wake-up stroke or unknown onset):

  • DWI-FLAIR mismatch pattern identifies patients who benefit from alteplase 6, 7
  • High quality evidence supports this approach when mechanical thrombectomy is not planned 6

Perfusion imaging-based selection (4.5-24 hours):

  • The 2025 HOPE trial 8 demonstrated that alteplase administered 4.5-24 hours after onset in patients with salvageable tissue on perfusion imaging increased functional independence (40% vs 26%, adjusted RR 1.52,95% CI 1.14-2.02, P=0.004)
  • This came with increased symptomatic ICH risk (3.8% vs 0.51%, P=0.01) but no mortality difference 8
  • A 2025 meta-analysis 9 confirmed extended window IVT improves excellent functional outcome (RR 1.24,95% CI 1.14-1.34) and good functional outcome (RR 1.18,95% CI 1.05-1.33)

Tenecteplase (0.25 mg/kg) in extended window:

  • A 2026 meta-analysis 10 showed TNK 4.5-24 hours after onset improved excellent functional outcomes (OR 1.34,95% CI 1.06-1.71, P=0.02)
  • Critical distinction: Benefits were substantially greater when EVT was unavailable (OR 1.46 for excellent outcome, OR 1.50 for good outcome) versus EVT-permitted settings (no significant functional benefit) 10
  • This establishes TNK as an alternative reperfusion strategy in resource-limited settings without thrombectomy access 10

Key Safety Considerations

Symptomatic ICH risk increases with extended window treatment:

  • Overall sICH risk with extended window IVT: OR 2.75-6.22 9, 11
  • Despite increased bleeding risk, mortality rates remain similar between IVT and control groups 9, 11, 8

Absolute contraindication: Do NOT administer fibrinolytics for isolated ST-segment depression (except when true posterior STEMI suspected) due to hemorrhagic stroke and major bleeding risk 3.

Clinical Decision Algorithm

For STEMI patients at non-PCI-capable hospitals:

  1. Symptom onset <12 hours + anticipated FMC-to-device >120 minutes → Administer fibrinolytic therapy immediately, then transfer for angiography within 3-24 hours 1, 3

  2. Symptom onset <12 hours + anticipated FMC-to-device ≤120 minutes → Transfer immediately for primary PCI 1, 3

  3. Symptom onset >12 hours with ongoing ischemia/hemodynamic instability → Transfer for PCI regardless of delay; consider fibrinolysis only if PCI truly impossible and large myocardium at risk 3

  4. Cardiogenic shock or severe heart failure → Transfer for PCI immediately, irrespective of any time delay 1, 5

For acute ischemic stroke patients presenting 4.5-24 hours:

  1. Obtain perfusion imaging (CT or MRI perfusion) or MRI with DWI-FLAIR to identify salvageable tissue 7, 8

  2. If salvageable tissue present AND no contraindications → Administer alteplase 0.9 mg/kg (max 90 mg) or tenecteplase 0.25 mg/kg 7, 8

  3. If large vessel occlusion AND thrombectomy available → Proceed directly to EVT; bridging thrombolysis benefit less clear in this context 10

  4. If thrombectomy unavailable → Extended window thrombolysis provides substantial benefit and should be strongly considered 10

Common Pitfalls

  • Do not delay fibrinolysis in STEMI waiting for transfer arrangements when FMC-to-device time will exceed 120 minutes—door-to-needle time should be ≤30 minutes 1
  • Do not use fibrinolysis beyond 6 hours in STEMI without compelling reasons (hemodynamic instability, large infarct, PCI truly impossible)—efficacy drops substantially 2
  • Do not administer stroke thrombolysis in extended window without advanced imaging—tissue-based selection is mandatory, not time-based alone 7, 8
  • Do not assume extended window stroke thrombolysis is futile—recent high-quality evidence demonstrates clear benefit with appropriate patient selection 8

References

Related Questions

Is intravenous alteplase (tPA) indicated up to 9 hours after symptom onset in acute ischemic stroke when advanced imaging shows a small infarct core and a substantial penumbra, and what are the eligibility criteria?
What is the step‑by‑step protocol for the acute management of an ischemic stroke, including assessment, imaging, eligibility for intravenous alteplase (tPA) and endovascular thrombectomy, and post‑treatment monitoring?
What is the recommended management of acute ischemic stroke according to recent guidelines based on time of symptom onset?
In a patient with acute ischemic stroke who declines mechanical thrombectomy, can intravenous thrombolysis with alteplase be administered?
What is the checklist for administering thrombolytic therapy (alteplase) to an adult with acute ischemic stroke?
Should patients on dialysis take finasteride?
If a patient taking Lovenox (enoxaparin) experiences brief blurred vision, what is the appropriate management?
Is there evidence that Melanotan (including Melanotan I and Melanotan II) increases the risk of skin cancer?
What prescription NSAID stronger than naproxen (Aleve) is appropriate for pain management?
Which antibiotics are non‑cardiotoxic and do not cause QT‑interval prolongation, arrhythmia, or cardiomyopathy?
What are the appropriate needle gauge and length for intramuscular injections in adults (including obese adults), children (10–30 kg and 30–50 kg), and infants (<10 kg) for deltoid and gluteal sites?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.